The US Food and Drug Administration (FDA) has approved Olumiant (baricitinib) for patients aged 12 years and older with severe alopecia areata, expanding the treatment’s...
Novartis has received traditional approval from the US Food and Drug Administration (FDA) for Fabhalta® (iptacopan) to slow kidney function decline in adults with primary...
Basel- April 2024- Roche announced that the U.S. Food and Drug Administration (FDA) has approved Alecensa® (alectinib) for adjuvant treatment following tumour resection f...
